<DOC>
	<DOCNO>NCT02677077</DOCNO>
	<brief_summary>The primary objective study retrospectively investigate proportion participant free new enlarge fluid-attenuated inversion recovery ( FLAIR ) lesion time approximately 300 Relapsing-Remitting Multiple Sclerosis ( RRMS ) participant regular MRI follow-up , receive natalizumab ≥24 month two different observational cohort : 1 ) approximately 230 participant Czech Republic ; 2 ) approximately 70 participant Belgium . The secondary objective study follow : Brain volume change various measure ; Changes number volume magnetic resonance imaging ( MRI ) lesion ; No evidence disease activity ( NEDA ) without brain volume change .</brief_summary>
	<brief_title>Clinical Disease Activity With Long Term Natalizumab Treatment</brief_title>
	<detailed_description>Natalizumab provide participant Biogen part study . Participants remain natalizumab therapy prescribe physician .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Diagnosis RRMS . Continuous treatment natalizumab ≥24 month . In case treatment interruption natalizumab ≥60 day total treatment period ≥24 month , treatment prior interruption analyze . Any data treatment interruption ( even patient restarts natalizumab ) analyzed/collected . ≥1 MRI scan sufficient quality reliable measurement . Baseline MRI scan ≤6 month prior natalizumab treatment acquire . ≥1 MRI scan sufficient quality reliable measurement take natalizumab treatment ≥6 month . EDSS ≤ 6.5 . Key Antinatalizumab antibody detection . Prior treatment alemtuzumab . Prior treatment mitoxantrone within 12 month first infusion natalizumab . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>RRMS</keyword>
	<keyword>MRI</keyword>
</DOC>